A Randomized, Open-Label, Multicenter Study of VELCADE With Rituximab or Rituximab Alone in Subjects With Relapsed or Refractory, Rituximab Naive or Sensitive Follicular B-Cell Non-Hodgkin's Lymphoma.

Trial Profile

A Randomized, Open-Label, Multicenter Study of VELCADE With Rituximab or Rituximab Alone in Subjects With Relapsed or Refractory, Rituximab Naive or Sensitive Follicular B-Cell Non-Hodgkin's Lymphoma.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Apr 2013

At a glance

  • Drugs Bortezomib (Primary) ; Rituximab
  • Indications Follicular lymphoma
  • Focus Biomarker; Pharmacogenomic; Registrational; Therapeutic Use
  • Most Recent Events

    • 09 Dec 2011 Results will be presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology, according to a Janssen-Cilag media release.
    • 12 Jun 2011 Patient-reported quality-of-life outcomes presented at the 16th Congress of the European Hematology Association.
    • 12 Jun 2011 Primary endpoint 'Progression-free-survival-duration' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top